OPK vs. INVA, IRWD, MNKD, LXRX, PCRX, DVAX, ADCT, VSTM, AVIR, and VNDA
Should you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Innoviva (INVA), Ironwood Pharmaceuticals (IRWD), MannKind (MNKD), Lexicon Pharmaceuticals (LXRX), Pacira BioSciences (PCRX), Dynavax Technologies (DVAX), ADC Therapeutics (ADCT), Verastem (VSTM), Atea Pharmaceuticals (AVIR), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "pharmaceutical preparations" industry.
Innoviva (NASDAQ:INVA) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.
Innoviva has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500.
OPKO Health received 203 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 65.70% of users gave OPKO Health an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
Innoviva has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
In the previous week, OPKO Health had 3 more articles in the media than Innoviva. MarketBeat recorded 8 mentions for OPKO Health and 5 mentions for Innoviva. OPKO Health's average media sentiment score of 1.74 beat Innoviva's score of 1.34 indicating that Innoviva is being referred to more favorably in the media.
OPKO Health has a consensus target price of $3.17, indicating a potential upside of 129.47%. Given Innoviva's higher probable upside, analysts plainly believe OPKO Health is more favorable than Innoviva.
99.1% of Innoviva shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 1.4% of Innoviva shares are held by insiders. Comparatively, 47.3% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Innoviva has a net margin of 58.21% compared to Innoviva's net margin of -31.44%. OPKO Health's return on equity of 28.94% beat Innoviva's return on equity.
Summary
Innoviva beats OPKO Health on 9 of the 17 factors compared between the two stocks.
Get OPKO Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OPKO Health Competitors List
Related Companies and Tools
